{
    "root": "53235270-6ffb-44c8-aa55-debf59e1d964",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "terbinafine hydrochloride",
    "value": "20250401",
    "ingredients": [
        {
            "name": "TERBINAFINE HYDROCHLORIDE",
            "code": "012C11ZU6G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77614"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        }
    ],
    "indications": {
        "text": "terbinafine tablets indicated treatment onychomycosis toenail fingernail due dermatophytes ( tinea unguium ) . prior initiating treatment , appropriate nail specimens laboratory testing [ potassium hydroxide ( koh ) preparation , fungal culture , nail biopsy ] obtained confirm diagnosis onychomycosis .",
        "doid_entities": [
            {
                "text": "tinea unguium (DOID:13074)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13074"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 prior administering , evaluate patients evidence chronic active liver disease . ( 2.1 ) \u2022 fingernail onychomycosis : one tablet , daily 6 weeks . ( 2.2 ) \u2022 toenail onychomycosis : one tablet , daily 12 weeks . ( 2.2 )",
        "doid_entities": [
            {
                "text": "liver disease (DOID:409)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_409"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic active liver",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_330064"
            }
        ]
    },
    "warningsAndPrecautions": "terbinafine tablets usp , 250 mg supplied light pink mottled surface , round , bi-convex , tablets debossed \u201c 501 \u201d one side plain side . bottles 30 tablets\u2026\u2026\u2026\u2026\u2026\u2026\u2026 ndc 82804-220-30 store terbinafine tablets 20\u00b0 25\u00b0c ( 68\u00b0 77 \u00b0f ) [ usp controlled room temperature ] ; tight container . protect light .",
    "adverseReactions": "terbinafine tablets contraindicated patients : \u2022chronic active liver disease [ ( 5.1 ) ] \u2022history allergic reaction oral terbinafine risk anaphylaxis [ ( 6.2 ) ]",
    "indications_original": "Terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium).\n                  Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis.",
    "contraindications_original": "\u2022 Prior to administering, evaluate patients for evidence of chronic or active liver disease. (2.1) \u2022 Fingernail onychomycosis: One tablet, once daily for 6 weeks. (2.2) \u2022 Toenail onychomycosis: One tablet, once daily for 12 weeks. (2.2)",
    "warningsAndPrecautions_original": "Terbinafine tablets USP, 250 mg are supplied as light pink with mottled surface, round, bi-convex, tablets debossed with \u201c501\u201d on one side and plain on the other side.\n                  Bottles of 30 tablets\u2026\u2026\u2026\u2026\u2026\u2026\u2026 NDC 82804-220-30\n                  Store terbinafine tablets at 20\u00b0 to 25\u00b0C (68\u00b0 to 77 \u00b0F) [see USP Controlled Room Temperature]; in a tight container. Protect from light.",
    "adverseReactions_original": "Terbinafine tablets are contraindicated in patients with:\n                  \n                     \n                        \u2022Chronic or active liver disease [see Warnings and Precautions (5.1)]\n                     \n                        \u2022History of allergic reaction to oral terbinafine because of the risk of anaphylaxis [see Adverse Reactions (6.2)]",
    "drug": [
        {
            "name": "terbinafine hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77614"
        }
    ]
}